Skyrizi (Risankizumab) has been recommended for the treatment of moderate to severe plaque psoriasis in adults in Scotland.
The Scottish Medicines Consortium (SMC) has today published its decision to recommend the biologic medicine, Skyrizi (Risankizumab), as a treatment for adults with moderate to severe plaque psoriasis in Scotland. This brings Scotland in line with England and Wales where the National Institute for Health and Care Excellence (NICE) approved Skyrizi for the treatment of psoriasis in August 2019.
Skyrizi may be prescribed to adult patients who have not responded to conventional systemic therapies (including ciclosporin, methotrexate and phototherapy), or who cannot tolerate these treatments.
How does Skyrizi work?
Skyrizi works by blocking the action of interleukin-23 (IL-23), a chemical ‘messenger’ in the immune system which signals other cells to cause inflammation. In people with psoriasis, the immune system is overactive and creates too much inflammation, which leads to the development of psoriasis symptoms. By blocking IL-23, Skyrizi aims to prevent some of that inflammation from occurring, leading to an improvement in psoriasis for some people who take it.
How is Skyrizi taken?
Skyrizi is taken by injection at a dose of 150mg (two injections of 75mg each) at weeks 0 and 4, and every 12 weeks from then on.
We will be publishing more information on Skyrizi in the near future. If you have any further questions, please get in touch.